Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were just diagnosed with AML and have a certain change in a gene called CEBPA.
- You are not healthy enough for standard strong chemotherapy (for example, due to older age, heart/lung/kidney/liver problems, on ongoing infection).
- You have not received prior chemotherapy or targeted drugs for this leukemia (except hydroxyurea).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with acute myeloid leukemia (AML) that has come back or hasn't responded to treatment, including those who have previously taken venetoclax. The goal is to see if this combo can help control the leukemia.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.